Abstract
Neuropathic pain (NP) resulting from chemotherapy, such as oxaliplatin (OXA), poses a significant therapeutic challenge and may lead to treatment discontinuation in cancer patients. Effective therapeutic approaches are crucial to improve the quality of life for these patients. Two promising interventions include vagal nerve electrostimulation (VNS), specifically non-invasive percutaneous …